The Effect of a Deworming Intervention to Improve Early Childhood Growth and Development in Resource-poor Areas
Primary Purpose
Malnutrition, Intestinal Diseases, Parasitic
Status
Completed
Phase
Phase 4
Locations
Peru
Study Type
Interventional
Intervention
Mebendazole
Usual care
Sponsored by
About this trial
This is an interventional treatment trial for Malnutrition focused on measuring preschool-age children, soil-transmitted helminths, growth, development, deworming
Eligibility Criteria
Inclusion Criteria:
- children attending any one of the participating study health centres for their routine 12-month growth and development visit
- children living in or near the study area
Exclusion Criteria:
- children who are attending the clinic for suspected STH infection
- children who have received deworming treatment in the six months prior to randomization
- parents planning to move outside of the study area within the next 12 months
- children under 12 months of age or 14 months of age or older
- children with serious congenital or chronic medical conditions and who would be considered by the attending staff not to benefit from deworming
Sites / Locations
- Asociacion Civil Selva Amazonica
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
Experimental
Experimental
Experimental
Placebo Comparator
Arm Label
Deworming at 12 months of age
Deworming at 18 months of age
Deworming at 12 and 18 months of age
Usual care
Arm Description
Outcomes
Primary Outcome Measures
Mean (± standard deviation) weight gain (kg)
Weight will be measured at baseline (12 months of age), and follow-up (18 and 24 months of age) to assess the effect of the deworming intervention on growth (in terms of weight)
Secondary Outcome Measures
Mean (± standard deviation) height gain (cm)
Height will be measured at baseline (12 months of age) and at follow-up (18 and 24 months of age) to evaluate the effect of the deworming intervention on growth (in terms of height)
Mean (± standard deviation) of the cognitive test score
Cognitive development will be assessed using the Bayley Scale of Infant Development. This scale provides a raw score and standardized score based on age-specific abilities. This will be measured at both baseline (12 months of age) and follow-up (at 24 months of age) to evaluate the effects of the deworming intervention on cognitive development.
Soil-transmitted helminth infection (Ascaris, Trichuris or hookworm) - prevalence (%) and intensity (mean eggs per gram)
Soil-transmitted helminth (STH) infection will be assessed from stool samples provided by participants. The Kato-Katz technique will be used to provide both an estimate of prevalence of each STH (e.g. % positive for each Ascaris, Trichuris, and/or hookworm) as well as an estimate of intensity of each STH (measured as mean eggs per gram of stool). This will be measured at baseline (12 months of age) and follow-up (18 and 24 months of age) to evaluate the effect of the deworming intervention on parasite prevalence and intensity.
Mean (± standard deviation) of the motor test score
Fine motor development will be assessed using the Bayley Scale of Infant Development. This scale provides a raw score and standardized score based on age-specific abilities. This will be measured at both baseline (12 months of age) and follow-up (at 24 months of age) to evaluate the effects of the deworming intervention on motor development.
Mean (± standard deviation) of the language test score
Receptive and expressive language development will be assessed using the Bayley Scale of Infant Development. This scale provides a raw score and standardized score based on age-specific abilities. This will be measured at both baseline (12 months of age) and follow-up (at 24 months of age) to evaluate the effects of the deworming intervention on language development.
Full Information
NCT ID
NCT01314937
First Posted
March 11, 2011
Last Updated
August 25, 2014
Sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
Collaborators
McGill University, Asociacion Civil Selva Amazonica, World Health Organization, Thrasher Research Fund, Canadian Institutes of Health Research (CIHR)
1. Study Identification
Unique Protocol Identification Number
NCT01314937
Brief Title
The Effect of a Deworming Intervention to Improve Early Childhood Growth and Development in Resource-poor Areas
Official Title
Improving Early Childhood Growth and Development in Resource-poor LMICs by Incorporating Deworming in Integrated Child Health Care
Study Type
Interventional
2. Study Status
Record Verification Date
August 2014
Overall Recruitment Status
Completed
Study Start Date
September 2011 (undefined)
Primary Completion Date
July 2013 (Actual)
Study Completion Date
July 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
Collaborators
McGill University, Asociacion Civil Selva Amazonica, World Health Organization, Thrasher Research Fund, Canadian Institutes of Health Research (CIHR)
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Worldwide, over 2 billion people suffer from worm infections in developing countries. These infections are especially damaging to the health of children, resulting in both short-term and lifelong disability. Older children with worm infections are more likely to be stunted, underweight, vulnerable to other illnesses and perform poorly in school compared to non-infected children. Large-scale deworming programs in school-age children are therefore recommended by the World Health Organization (WHO). WHO also recommends deworming of preschool-age children (as of 12 months of age) in these areas; however, the benefits of deworming, especially in the 12-24 month age group, have been inadequately studied. This knowledge is urgently needed as studies show that all children have a similar potential for healthy growth and development, provided that appropriate nutrition and health interventions are given in the critical window of opportunity before the age of two.
Therefore, the investigators are proposing to undertake a randomized controlled trial to determine the effect of deworming program for improving growth and development in children between 12 and 24 months of age. Our results will provide solid rigorous evidence on if, when, and how often, deworming should be integrated into routine child health care packages provided by Ministries of Health in the 130 countries in the world where worm infections are endemic.
Detailed Description
Worldwide, over 2 billion people suffer from worm infections (hookworm, Ascaris and Trichuris, collectively referred to as soil-transmitted helminths (STHs)) in developing countries. STHs contribute to the overwhelming burden of poverty and deprivation in areas where adverse health, social, economic, education and other related factors predominate. STH infection in childhood results in short-term and lifelong disability, including malnutrition (e.g. underweight, stunting and wasting), cognitive impairment and increased susceptibility to other infection, among others. Mass deworming programs in school-age children are recommended by the World Health Organization (WHO). WHO also recommends deworming of preschool children (as of 12 months of age) in endemic areas; however, the benefits of deworming on improving growth and development, especially in the 12-24 month age group, have been inadequately studied. This knowledge is crucial because, with appropriate nutrition and health interventions, all children have a similar potential for healthy growth and development, provided that such interventions occur in the critical window of opportunity before the age of two.
Therefore, this double-blind randomized controlled trial will assess the benefit of deworming (mebendazole), integrated into routine child health care visits in a highly STH-endemic area (Iquitos, Peru), on the primary outcome of weight gain. Timing, frequency and impact of deworming will be considered. A total of 1760 children will be recruited at their routine 12-month check-up visit and randomly assigned to one of four intervention groups: Group 1 will receive usual care and mebendazole (single dose 500 mg) at their 12-month visit and usual care and a placebo tablet at their 18-month visit; Group 2 will receive usual care and a placebo tablet at their 12-month visit and usual care and mebendazole at their 18-month visit; Group 3 will receive usual care and mebendazole at both their 12-month and 18-month visit; and Group 4 will receive usual care and placebo at both their 12-month and 18-month visit. Usual care will consist of age-appropriate immunizations, supplements and other Peruvian Ministry of Health-recommended interventions. All children will be followed up to their 24-month visit and all will be given mebendazole at that time.
Additional secondary outcomes include length gain, motor and cognitive development and STH prevalence and intensity.
Improving child health is a priority area in global health research and a focus of the Millennium Development Goals. Early preschool-age children are at the most critical stage of growth and development and have been neglected in deworming programs. It is anticipated that the results will inform evidence-based policy on the provision of an integrated health package for young children in endemic areas and ultimately contribute to the reduction of health inequities in this vulnerable group.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Malnutrition, Intestinal Diseases, Parasitic
Keywords
preschool-age children, soil-transmitted helminths, growth, development, deworming
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
1760 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Deworming at 12 months of age
Arm Type
Experimental
Arm Title
Deworming at 18 months of age
Arm Type
Experimental
Arm Title
Deworming at 12 and 18 months of age
Arm Type
Experimental
Arm Title
Usual care
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
Mebendazole
Other Intervention Name(s)
Vermox, Nemasole, Pantelmin
Intervention Description
Single-dose 500 mg mebendazole tablet
Intervention Type
Other
Intervention Name(s)
Usual care
Other Intervention Name(s)
Standard of care, routine health care services
Intervention Description
Routine child health interventions (e.g. age-specific immunizations, supplementations, etc.)
Primary Outcome Measure Information:
Title
Mean (± standard deviation) weight gain (kg)
Description
Weight will be measured at baseline (12 months of age), and follow-up (18 and 24 months of age) to assess the effect of the deworming intervention on growth (in terms of weight)
Time Frame
from 12 to 24 months of age
Secondary Outcome Measure Information:
Title
Mean (± standard deviation) height gain (cm)
Description
Height will be measured at baseline (12 months of age) and at follow-up (18 and 24 months of age) to evaluate the effect of the deworming intervention on growth (in terms of height)
Time Frame
from 12 to 24 months of age
Title
Mean (± standard deviation) of the cognitive test score
Description
Cognitive development will be assessed using the Bayley Scale of Infant Development. This scale provides a raw score and standardized score based on age-specific abilities. This will be measured at both baseline (12 months of age) and follow-up (at 24 months of age) to evaluate the effects of the deworming intervention on cognitive development.
Time Frame
from 12 to 24 months of age
Title
Soil-transmitted helminth infection (Ascaris, Trichuris or hookworm) - prevalence (%) and intensity (mean eggs per gram)
Description
Soil-transmitted helminth (STH) infection will be assessed from stool samples provided by participants. The Kato-Katz technique will be used to provide both an estimate of prevalence of each STH (e.g. % positive for each Ascaris, Trichuris, and/or hookworm) as well as an estimate of intensity of each STH (measured as mean eggs per gram of stool). This will be measured at baseline (12 months of age) and follow-up (18 and 24 months of age) to evaluate the effect of the deworming intervention on parasite prevalence and intensity.
Time Frame
from 12 to 24 months of age
Title
Mean (± standard deviation) of the motor test score
Description
Fine motor development will be assessed using the Bayley Scale of Infant Development. This scale provides a raw score and standardized score based on age-specific abilities. This will be measured at both baseline (12 months of age) and follow-up (at 24 months of age) to evaluate the effects of the deworming intervention on motor development.
Time Frame
from 12 to 24 months of age
Title
Mean (± standard deviation) of the language test score
Description
Receptive and expressive language development will be assessed using the Bayley Scale of Infant Development. This scale provides a raw score and standardized score based on age-specific abilities. This will be measured at both baseline (12 months of age) and follow-up (at 24 months of age) to evaluate the effects of the deworming intervention on language development.
Time Frame
from 12 to 24 months of age
10. Eligibility
Sex
All
Minimum Age & Unit of Time
12 Months
Maximum Age & Unit of Time
24 Months
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
children attending any one of the participating study health centres for their routine 12-month growth and development visit
children living in or near the study area
Exclusion Criteria:
children who are attending the clinic for suspected STH infection
children who have received deworming treatment in the six months prior to randomization
parents planning to move outside of the study area within the next 12 months
children under 12 months of age or 14 months of age or older
children with serious congenital or chronic medical conditions and who would be considered by the attending staff not to benefit from deworming
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Theresa W Gyorkos, PhD
Organizational Affiliation
McGill University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Martin Casapia, MD, MPH
Organizational Affiliation
Asociacion Civil Selva Amazonica
Official's Role
Principal Investigator
Facility Information:
Facility Name
Asociacion Civil Selva Amazonica
City
Iquitos
State/Province
Loreto
Country
Peru
12. IPD Sharing Statement
Citations:
PubMed Identifier
26426270
Citation
Joseph SA, Casapia M, Montresor A, Rahme E, Ward BJ, Marquis GS, Pezo L, Blouin B, Maheu-Giroux M, Gyorkos TW. The Effect of Deworming on Growth in One-Year-Old Children Living in a Soil-Transmitted Helminth-Endemic Area of Peru: A Randomized Controlled Trial. PLoS Negl Trop Dis. 2015 Oct 1;9(10):e0004020. doi: 10.1371/journal.pntd.0004020. eCollection 2015. Erratum In: PLoS Negl Trop Dis. 2015 Dec;9(12):e0004288.
Results Reference
derived
Learn more about this trial
The Effect of a Deworming Intervention to Improve Early Childhood Growth and Development in Resource-poor Areas
We'll reach out to this number within 24 hrs